BPC
DNLI icon

Bryce Point Capital’s Denali Therapeutics DNLI Stock Holding History

Bryce Point Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,550
Closed -$419K – 260
2024
Q4 		$419K Buy
+20,550
New +$526K 0.12% 379

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bryce Point Capital's DNLI Position: Q1 2025 in Review

Bryce Point Capital sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 20,550 shares — an estimated $419K sold.

Bryce Point Capital first reported a position in DNLI in Q4 2024 and held it in 1 quarter. The position peaked at $419K in Q4 2024. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

  • Bryce Point Capital reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bryce Point Capital sold 20,550 Denali Therapeutics shares in Q1 2025, an estimated $419K.
  • Bryce Point Capital first reported a position in Denali Therapeutics in Q4 2024 and held it in 1 quarter.
  • Bryce Point Capital's Denali Therapeutics position peaked at $419K in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Bryce Point Capital's 13F filing for Q1 2025, filed 7 May 2025.